Is AMRZ a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Amrize (AMRZ) rests on Mega-project demand for cement and aggregates: Management attributes the second quarter's 6.7% organic growth to data centers, energy projects, advanced manufacturing plants and infrastructure modernization, and says it is signing multi-year supply agreements against those starts. The bear case rests on construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output. Analysts covering it publish targets from $48.00 to $70.00 against a $46.64 price, so even the professionals disagree by 36% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Amrize (NYSE: AMRZ) is the North American building-materials company that Holcim separated on June 23, 2025, distributing 100% of Amrize shares to Holcim holders as a dividend in kind. The standalone company holds Holcim's US, Canadian, Swiss and Jamaican operations plus support functions in Colombia, runs more than 1,000 sites, employs over 19,000 people and is dual listed on the NYSE and the SIX Swiss Exchange with corporate offices in Chicago and Zug. It reports in two segments. Building Materials (~$8.5 billion of 2025 revenue) sells cement, aggregates, ready-mix concrete and asphalt. Building Envelope (~$3.3 billion) sells commercial and residential roofing, insulation, waterproofing, coatings, adhesives and sealants, a business largely assembled through the Malarkey (2022) and Duro-Last (2023) acquisitions. The investment picture in August 2026 is a good-volumes, bad-costs story. Second-quarter revenue rose 8.6% to ~$3.49 billion with 6.7% organic growth, cement tons up 5.0% and aggregates tons up 6.5%, and management raised full-year revenue guidance to $12.5 billion to $12.7 billion on mega-project demand from data centers, energy and advanced manufacturing. In the same release it cut adjusted EBITDA guidance to $3.1 billion to $3.2 billion from $3.25 billion to $3.34 billion, blaming oil-driven freight, diesel and raw-material inflation that pricing has not yet caught. Building Envelope segment EBITDA fell 5.2% year over year despite 9.4% revenue growth. The company also disclosed a revision of prior-period financial statements, mainly an understated extended-warranty deferred-revenue balance of ~$78 million at the end of 2025 tied to Duro-Last and Malarkey, which it judged immaterial to prior periods but material if corrected in one quarter. The stock closed at a 52-week low of ~$46.64 on August 7, roughly 29% below its February high.

The bull case: what would have to be true for $70.00

The most optimistic published target on AMRZ is $70.00, +50.1% from the $46.64 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Mega-project demand for cement and aggregates

Management attributes the second quarter's 6.7% organic growth to data centers, energy projects, advanced manufacturing plants and infrastructure modernization, and says it is signing multi-year supply agreements against those starts. Cement volumes were up 5.0% and aggregates up 6.5% in the quarter, both described as above market. This is the part of the business where Amrize sets price rather than absorbing it: aggregates pricing rose 4.0% on a constant-currency, freight-adjusted basis.

2. Pricing catching up to oil-linked costs

The guidance cut is a timing argument rather than a demand argument. Cement pricing was down 0.2% year over year in Q2 but improved 2.1% sequentially as April increases phased in, and Building Envelope put further increases into effect in July with more planned for August. Whether second-half price-cost recovers as management expects is the single largest swing factor in the 2026 numbers, and it depends partly on where oil goes.

3. Bolt-on M&A in a fragmented aggregates market

Amrize closed PB Materials in West Texas in the first quarter and Rapid Redi-Mix in Dallas-Fort Worth in July, both bolted onto an existing cement and aggregates network for freight and vertical-integration synergies. Acquisitions contributed ~$54 million of Building Materials revenue in the quarter. Net leverage of 1.7x and an investment-grade posture leave room to keep buying, though capex of ~$900 million in 2026 competes for the same dollars.

4. Capital returns from a standalone balance sheet

The company returned ~$502 million in the second quarter: ~$197 million of buybacks under a newly launched $1 billion authorization plus ~$305 million of dividends, including a $0.44 special for 2025 and the first $0.11 quarterly payment. A second $0.11 quarterly dividend was declared for payment in August. Dividends are paid from Swiss capital-contribution reserves and are not subject to Swiss withholding tax, which matters to the after-tax yield US holders actually receive.

The bear case: what would have to be true for $48.00

The most pessimistic published target is $48.00, +2.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Amrize is worth if the risks below bite instead of the drivers above.

Construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output. The immediate pressure is input costs: oil-linked freight, diesel, bitumen and roofing raw materials compressed consolidated adjusted EBITDA margin by 80 basis points year over year in Q2 and Building Envelope margin by 350 basis points, and the fix depends on price increases sticking with customers. The prior-period revision, centered on understated extended-warranty deferred revenue from the Duro-Last and Malarkey acquisitions, is a control question at a company barely a year into standalone reporting, and it is the kind of disclosure that can attract plaintiff-firm attention even when management concludes the amounts were immaterial. Free cash flow was a use of ~$986 million in the first half, worse than the prior year on higher capex, so the full-year cash story rests entirely on a seasonally strong second half. The company is also Swiss-incorporated with a second listing in Zurich, which adds governance and tax mechanics that a purely domestic peer does not carry.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding AMRZ already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on AMRZ

19 analysts cover AMRZ, with an average target of $61.83 (+32.6% against $46.64) and a split of 12 buy, 8 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the AMRZ forecast and price target page.

How is AMRZ valued? (as of August 2026)

Price
$46.64
Market cap
$25.82B
P/E (TTM)
22.32
Forward P/E
14.79
Price / book
1.97
52-week range
$46.31 to $65.94

Snapshot for AMRZ as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

  • Revenue (TTM): ~$12.2B, with Q2 2026 at ~$3.49B, up 8.6% year over year
  • Adjusted EBITDA (TTM): ~$3.0B, a margin of ~24.9%; Q2 margin was 28.2%, down 80 bps
  • Net income / diluted EPS (TTM): ~$1.2B and ~$2.23; Q2 net income was ~$476M, up 14.4%
  • Market cap and P/E: ~$25.9B at a ~$46.64 close, or roughly 21x trailing earnings
  • Enterprise value / EBITDA: ~10x, on ~$5.3B of net debt and 1.7x net leverage
  • FY 2026 guidance: Revenue $12.5B to $12.7B (raised); adjusted EBITDA $3.1B to $3.2B (cut from $3.25B to $3.34B)

The multiple sits below pure-play aggregates names: Vulcan trades near 33x trailing earnings and Martin Marietta near 13x on a very different earnings base, while CRH is near 17x. Part of Amrize's discount is the Building Envelope segment, which is a manufacturing business with different margins and a different cost structure than a quarry. The rest reflects a one-year operating history as a standalone, a guidance cut on its second reported quarter of 2026, and the prior-period revision disclosed alongside it.

How do you decide if AMRZ is a buy?

Rather than asking whether AMRZ is a buy in the abstract, it tends to help to answer four questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold AMRZ indirectly through an index or sector ETF before adding more.

What would change your mind on AMRZ

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Mega-project demand for cement and aggregates stalls in the reported numbers rather than in the narrative around them.
  • Bear case breaks if: construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the AMRZ stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AMRZ against your real portfolio and see your actual exposure before deciding.

Investing in Amrize with AI

Connect the broker you already use and ask Walnut's AI how AMRZ fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

FAQ

Is AMRZ a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Mega-project demand for cement and aggregates, with revenue (ttm) at ~$12.2B, with Q2 2026 at ~$3.49B, up 8.6% year over year. The bear case rests on construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output. Analysts covering it are spread from $48.00 to $70.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell AMRZ?

+

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $48.00, +2.9% from the $46.64 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for AMRZ?

+

Mega-project demand for cement and aggregates. Management attributes the second quarter's 6.7% organic growth to data centers, energy projects, advanced manufacturing plants and infrastructure modernization, and says it is signing multi-year supply agreements against those starts. The most optimistic analyst target on AMRZ is $70.00, +50.1% from the $46.64 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for AMRZ?

+

Construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output. The immediate pressure is input costs: oil-linked freight, diesel, bitumen and roofing raw materials compressed consolidated adjusted EBITDA margin by 80 basis points year over year in Q2 and Building Envelope margin by 350 basis points, and the fix depends on price increases sticking with customers. The prior-period revision, centered on understated extended-warranty deferred revenue from the Duro-Last and Malarkey acquisitions, is a control question at a company barely a year into standalone reporting, and it is the kind of disclosure that can attract plaintiff-firm attention even when management concludes the amounts were immaterial. Free cash flow was a use of ~$986 million in the first half, worse than the prior year on higher capex, so the full-year cash story rests entirely on a seasonally strong second half. The company is also Swiss-incorporated with a second listing in Zurich, which adds governance and tax mechanics that a purely domestic peer does not carry. The most pessimistic published target is $48.00, +2.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

What does Amrize do?

+

North American cement, aggregates, ready-mix and roofing supplier separated from Holcim in June 2025, spanning building materials and building envelope.

What would have to change for AMRZ to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Mega-project demand for cement and aggregates) stalling in the reported numbers rather than in the narrative, the risk above (construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What is AMRZ and when did it start trading?

+

AMRZ is the NYSE ticker for Amrize Ltd. Holcim completed the spin-off on June 23, 2025, distributing 100% of Amrize's shares to Holcim shareholders as a pro rata dividend in kind based on the June 20, 2025 record date. About 553.1 million shares were distributed. Amrize is also listed on the SIX Swiss Exchange under the same ticker.

What exactly did the standalone company get in the spin-off?

+

Amrize holds Holcim's business, activities and operations in the United States, Canada, Switzerland and Jamaica, plus certain support operations in Colombia. In practice that is the North American cement, aggregates, ready-mix and asphalt network alongside the roofing and wall-systems business built from the Malarkey and Duro-Last acquisitions. Holcim kept Europe, Latin America, Africa and Asia.

How did Amrize do in the second quarter of 2026?

+

Revenue rose 8.6% to ~$3.49 billion with 6.7% organic growth. Net income rose 14.4% to ~$476 million, or $0.86 per diluted share, and adjusted EBITDA rose 5.8% to ~$986 million. Margins compressed: consolidated adjusted EBITDA margin fell 80 basis points and Building Envelope segment margin fell 350 basis points on freight and raw-material costs.

Walnut is informational, not investment advice, and gives no verdict on AMRZ. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.

Related stocks

    Is AMRZ a Buy or a Sell? The Bull and Bear Case (2026) - Walnut AI Investing App